Digital Pass Select

Register today

AACC is continuing the Digital Pass Select registration option. Digital Pass Select enables you to livestream the Sunday Plenary and 16 select hot-topic sessions on a digital platform. With this registration, you can also watch these sessions on-demand starting 24 hours after they air live and continuing for an entire month following the conference. Digital Pass Select does not replace the in-person experience, but it does provide a sample of the great session content to individuals unable to travel.

  • July 24 – July 28: Access to select sessions via livestream (listing below).
  • July 26 – July 28: Access to ePoster presentations.
  • July 29 – August 29: Continued on-demand access to ePosters and select sessions (listing below).

Learn more about registration fees here and explore the list of select sessions available through Digital Pass Select by day below. (You can also search the full list of sessions at the AACC Annual Scientific Meeting here.)

Note: All times below are in U.S. Central Time.

Sunday, July 24

Monday, July 25

Tuesday, July 26

Wednesday, July 27

Thursday, July 28


SUNDAY, JULY 24, OPENING PLENARY

11001 Biomedical Informatics Strategies to Enhance Individualized Predictive Models

Sunday, July 24, 2022 | 5 – 6:30 p.m.
Precision medicine is based on the development of individualized estimates for patients. There is an increasing use of artificial intelligence (AI) in clinical prediction models (e.g., severity scores, sepsis prediction). Although adoption is still sparse among clinicians, we may soon have a long list of predictive models for a given problem and may have a difficult time deciding which one is best. In this plenary session, Dr. Ohno-Machado will introduce how AI models are developed, tested, and validated. Dr. Ohno-Machado will then discuss performance measures that may help clinicians select these models for routine use. This will be presented in a tutorial format that reviews the main differences between statistical models (e.g., regression) and AI models (e.g., neural networks), and describes how different evaluation measures including model simplicity, explainability, and classification performance can be assessed and compared. The goal is to demystify AI for clinicians and biomedical researchers.

  • Lucila Ohno-Machado, MD, PhD, MBA

MONDAY, JULY 25

32101 Bad, Better, Best: Putting Machine Learning Models to the Test (President's Invited Session)

Monday, July 25, 2022 | 10:30 a.m. – 12 p.m.
One of the most exciting new frontiers in laboratory medicine is the application of data analytics techniques to laboratory data. Machine Learning has emerged as a valuable tool for the achieving better diagnostic information from existing laboratory medicine data, thus improving the lab's ability to add interpretive value to the information that is delivered to rest of the health care system. Although this area has generated much excitement, it is important for laboratories to understand common pitfalls in applying machine learning to laboratory data. This interactive session will cover common pitfalls and associated best practices in the development, validation, and reporting of machine learning applications using a case-based, compare/contrast approach with audience polling.

  • Stephen Master, MD, PhD, FAACC | Children's Hospital of Philadelphia (moderator)
  • T. Scott Isbell, PhD, DABCC, FAACC | Saint Louis University School of Medicine (facilitator)
  • Shannon Haymond, PhD, DABCC, FAACC | Ann & Robert H. Lurie Children's Hospital of Chicago
  • Christopher McCudden, PhD, DABCC, NRCC, FACB | The Ottawa Hospital General Campus

32110 Preanalytical Challenges of Blood, Sweat, and Urine Collection in Pediatric Populations

Monday, July 25, 2022 | 10:30 a.m. – 12 p.m.
Preanalytical variables are a significant source of error in laboratory testing, and this is particularly true in the pediatric patient population. Challenges arise due to low blood volume, small veins, inability to provide a urine sample, and more. These issues require unique solutions. This session will review 1) the appropriate approaches and pitfalls in umbilical cord blood collection, 2) challenges in pediatric urine collections and the impact on test results, and 3) preanalytical factors that impact successful sweat collections from babies.

  • Amy Pyle-Eilola, PhD | Nationwide Children's Hospital (moderator)
  • Stefani Thomas, PhD, DABCC, NRCC | University of Minnesota
  • Khushbu Patel, PhD, DABCC, FAACC | Children's Hospital of Philadelphia

32442 Cannabis and Driving: Biomarkers, Performance, and Officer Observations

Monday, July 25, 2022 | 12:30 – 2 p.m.
This session is intended for toxicologists and others who are interested in the effects of cannabis on driving performance. Identifying drivers who have recently used cannabis or cannabis products is challenging because of the variability in dosing materials, routes of administration and pharmacokinetics. Oral fluid, breath, and blood specimens are the primary biological materials being studied to help identify recent use of cannabis products. In this session we will present an update on biomarkers of cannabis use and describe strengths and weaknesses of approaches that use bio-fluids to support identification of driving under the influence. We will also describe results of the largest placebo controlled randomized trial conducted to date that evaluated the effect of cannabis on simulated driving performance. Predictive values of approaches using "cutoff" concentrations of cannabinoids in various biological fluids along with police officer observations will be described.

  • Robert Fitzgerald, PhD, DABCC, NRCC, FAACC | University of California, San Diego (moderator)
  • Thomas Marcotte, PhD | University of California, San Diego

32446 Population Genomics Health and Precision Medicine (Chair's Invited Session)

Monday, July 25, 2022 | 12:30 – 2 p.m.
Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions, for example in individuals with cardiovascular and cancer predispositions. There are now several emerging efforts demonstrating the application of genomics for medical care, in both healthy and disease cohorts, and at both institutional and national levels, including the All of Us Research Program as well as the BioMe genomic screening program. However, research is still needed to develop standards for genomic screening, particularly in non-European ancestry populations who are vastly underrepresented in genomic medicine research. This session will focus on advances in precision health large-scale research programs, genomic medicine and the application of precision medicine, with a focus on efforts to better serve underrepresented populations and ameliorate health inequities.

  • Linnea Baudhuin, PhD, DABMGG, FACMG | Mayo Clinic (moderator)
  • Stephanie Devaney, PhD | All of Us Research Program, National Institutes of Health
  • Eimear Kenny, PhD | Institute for Genomic Health/Icahn School of Medicine at Mount Sinai

32229 Updates on Chronic Kidney Disease Diagnosis: New Race Neutral eGFR, Measured GFR, and Urine Albumin-to-Creatinine Ratio

Monday, July 25, 2022 | 2:30 – 4 p.m.
Kidney Disease Initiative Global Outcome 2012 guidelines established a diagnostic classification of CKD using two laboratory parameters: estimated glomerular filtration rate (eGFR) from serum creatinine (sCRE) and urinary albumin-to-creatinine ratio (ACR) [or protein:creatinine ratio (PCR)]. Recently, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) joint taskforce recommended the use of CKD-EPI creatinine eGFR equation refit without the race variable, as well as increased use of serum cystatin C for kidney health estimation. However, the directly measured GFR (mGFR) through iohexol has become a standard procedure in some kidney centers. How do eGFR and mGFR compare? How reliable and standardized are serum creatinine, albuminuria, and proteinuria methods? Is the recommended race-neutral eGFR equation the best one for all patients? What are the pitfalls in ACR or PCR measurements? This session, developed with the IFCC Committee on Kidney Diseases will address these critical issues in kidney health.

  • Pradip Datta, PhD, DABCC | Siemens Healthcare Diagnostics
  • Jesse Seegmiller, PhD, DABCC | University of Minnesota

32230 Valid Vital LDTs: Current State of Regulation Legislation of Laboratory-Developed Tests

Monday, July 25, 2022 | 2:30 – 4 p.m.
Changes in the regulation of laboratory-developed tests (LDTs) in the United States (US) has been the subject of debate, proposals, guidance, legislation, and discussion for decades. Multiple legislative bills have been recently introduced into the US congress and viable routes for passage currently exist. These legislative bills propose changes in the regulatory landscape of LDTs that will impact patients, laboratories, and physicians, and have the potential to dramatically alter the practice of medicine in the US. Join experts from leading professional organizations as they discuss key elements of the current legislative proposals, the state of the bills, and address questions posed by the audience. The panel members recently participated in a joint AACC/ACMG/AMP/APC webinar discussing this topic and a robust number of questions across the breadth of legislation and impacts on LDTs. The panel looks forward to an interactive discussion addressing key elements of the legislation and audience questions.

  • Eric Konnick, MD | University of Washington (moderator)
  • Karen Kaul, MD, PhD | Evanston Hospital
  • David Flannery, MD | Cleveland Clinic
  • Dennis Dietzen, PhD, DABCC, FAACC | Washington University School of Medicine
  • Jonathan Genzen, MD, PhD | ARUP Laboratories

TUESDAY, JULY 26

33102 Addressing Preanalytical Issues for Blood Collection and Testing Outside Conventional Locations

Tuesday, July 26, 2022 | 10:30 a.m. – 12 p.m.
Despite substantial efforts, preanalytical variables continue to be the leading cause of errors for the clinical laboratory. If blood collection by non-phlebotomists or skilled nurses and testing by non-clinical laboratorians is to be moved to non-conventional locations, e.g., at home, pharmacies, or remote other locations, preanalytical errors will increase leading to need for recollection and medical errors. The clinical laboratory may be held responsible for ensuring the quality of distributed testing. Through lectures and an extended panel discussion, we discuss important issues such as improvements in capillary blood collection via fingerstick, the mechanism, detection and preventative measures for sample hemolysis, and the potential value of collecting and testing dried blood spots.

  • Alan Wu, PhD | University of California, San Francisco (moderator)
  • Susan Evans, PhD, FAACC | BioDecisions Consulting
  • Robert Christenson, PhD, DABCC, FACB | University of Maryland School of Medicine

33109 The Clinical Laboratory Workforce: Essential Before, Critical Now, and a Blueprint for a Stronger Future

Tuesday, July 26, 2022 | 10:30 a.m. – 12 p.m.
Given the essential role of the laboratory workforce in the healthcare system, it is especially important both to understand the factors contributing to the challenges that affect the current supply of and pathways into clinical laboratory professions, as well as to determine how to address them. Results from interviews and focus groups conducted for the study, Garcia et al, strongly emphasize that meeting future workforce needs will require actions by and collaboration among a wide range of stakeholders. These groups include the laboratory (e.g., institutions and employers), laboratory training programs, and professional organizations. By implementing the actions outlined in the blueprint developed by the American Society for Clinical Pathology and the University of Washington Center for Health Workforce Studies, they can collectively improve the recognition of the current clinical laboratory workforce, increase the opportunities for new entrants into the workforce, and strengthen the pathways into and among these careers.

  • Bianca Frogner, PhD | University of Washington Center for Health Workforce Studies (moderator)
  • Edna Garcia, MPH | American Society for Clinical Pathology

33225 Point-of-Care Testing: Meeting Patient Needs in New Ways

Tuesday, July 26, 2022 | 2:30 – 4 p.m.
Point-of-care testing (POCT) is laboratory testing conducted close to the site of patient care. Traditionally performed in the hospital setting, the portability and ease-of-use creates the opportunity for POCT to meet clinical needs in new ways. This session will explore how POCT is being deployed in a variety of patient care settings through lecture and interactive discussion with the audience. The clinical utility of POCT and changing needs during the pandemic will be a focus of this session.

  • James Nichols, PhD, DABCC, FAACC | Vanderbilt University Medical Center (moderator)
  • Yukari Manabe, MD, FIDSA, FRCP | Johns Hopkins Center for Global Health

33231 Xenotransplantation of a Porcine Heart to a Human: A New Era Begins

Tuesday, July 26, 2022 | 2:30 – 4 p.m.
On January 7, 2022, a new era began with the first successful xenotransplant of a porcine heart from a genetically modified animal into a human. This session will include a cardiac surgeon from the case, the medical director of the Cardiac Intensive Care Unit that directed post transplantation care and the infectious disease physician responsible for assuring safety and monitoring during this groundbreaking procedure and the patient's convalescence. This session will include discussion of the donor animal's genetic modifications, logistics of the surgical procedure, infectious disease considerations, and point of care testing support necessary for the Cardiac intensive care unit. Specific laboratory medicine considerations will include handling precautions, the validity of common tests and unmet needs in xenotransplantation. The special infectious disease precautions followed will be a feature of the session. The session will have a moderated panel discussion with the xenotransplant team that will take audience questions.

  • Robert Christenson, PhD, DABCC, FACB | University of Maryland School of Medicine (moderator)
  • Bartley Griffith, MD | University of Maryland School of Medicine
  • Alison Grazioli, MD | University of Maryland School of Medicine
  • Kapil Saharia, MD | University of Maryland School of Medicine

WEDNESDAY, JULY 27

34108 JALM Hot Topics: Current Practice and Future Promise of Immunology Laboratory Medicine

Wednesday, July 27, 2022 | 10:30 a.m. – 12 p.m.
Immunology is the medical science dealing with the immune system's cell-mediated and humoral aspects of immunity and immune responses. AACC's Journal of Applied Laboratory Medicine 2022 special issue focuses on immunology practice and this session will highlight progress in autoimmune diagnostics and their use in modern and future practice. One talk presents the diagnostic performance of current neural antibody testing for autoimmune encephalitis, a field of study that is emerging in part because of knowledge developing on the development neuronal antibodies. Also, current international guidance on antinuclear antibody testing, a topic that is essential for the effective practice of Immunology practice, will be discussed with expert insight on the interpretation of evidence. This symposium's third part will speak to future practice, and Immunology's expanding scope of surveying the function and dysfunction of autoimmunity. This session will provide key takeaways for professionals at all levels of knowledge and experience in immunology.

  • Vathany Kulasingam, PhD, FCACB | University Health Network/University of Toronto (moderator)
  • Edward Chan, PhD | University of Florida Health
  • Adrian Budhram, MD, FRCPC | Western University
  • Susan Fink, MD, PhD | University of Washington

34111 Testing Strategies for Detecting Pediatric Drug Exposure: A Case Based Discussion

Wednesday, July 27, 2022 | 10:30 a.m. – 12 p.m.
The young victims of changing drug use trends spurred on by the opioid epidemic and COVID-19 pandemic are often overlooked. The opioid epidemic has led to an alarming increase in unintentional pediatric drug exposure. The co-occurring COVID-19 pandemic has led to an increase in prescription drug misuse among early adolescents. These trends call for thoughtful reconsideration of laboratory-based testing strategies for detecting drug exposure in pediatric patients. Discussion of critical questions, such as what immunoassays should be included in urine toxicology panels, what are the consequences of inaccurate screening results, should pediatric testing only be done by definitive mass spectrometry-based methods, is essential. This session will highlight these topics through the perspectives of two different clinical laboratory's unique approaches to pediatric drug testing. Clinical cases will be used to highlight the advantages and disadvantages of different approaches.

  • Kara Lynch, PhD, DABCC, FAACC | University of California, San Francisco/Zuckerberg SFGH Clinical Laboratories (moderator)
  • Stephen Roper, PhD | Washington University School of Medicine

34221 Cardiovascular Risk Assessment Update: Clinical Utility of Lipids, Lipoproteins, and Genetic Panels

Wednesday, July 27, 2022 | 2:30 – 5 p.m.
Biomarkers of cardiovascular disease and guidelines for their use continue to evolve at a rapid pace. A panel of experts will present the latest evidence and societal recommendations. Topics covered will include new risk estimators, LDL calculations, fasting expectations, apolipoprotein B, lipoprotein (a), and personalized genomic panels. Significant time will be devoted to townhall-style audience questions and answer with a focus on empowering laboratory scientists to better support their practice and make informed decisions on their cardiovascular disease testing menu.

  • Jeff Meeusen, PhD, DABCC | Mayo Clinic (moderator)
  • Alan Remaley, MD, PhD | National Institutes of Health
  • Allan Sniderman, MD | Royal Victoria Hospital
  • Maseko Ueda, MD | University of Pennsylvania
  • Leslie Donato, PhD, DABCC | Mayo Clinic

34227 Optimal Testing: AACC’s Guide to Lab Test Utilization

Wednesday, July 27, 2022 | 2:30 – 5 p.m.
Inappropriate lab test utilization includes overutilization, misutilization, and underutilization. It adversely affects patient care and is a financial burden to both the patient and the healthcare system. To address this serious issue, AACC Academy and Science and Practice Core Committee have formed a joint Task Force to develop AACC's Guide to Lab Test Utilization. The Task Force has developed and published 20 guidance documents with more to come. These guidance documents are important resources that outline appropriate test utilization and are targeted to clinical laboratorians, clinicians, and other medical professionals that conduct or order clinical tests. This session will outline the needs assessment for these guidance documents and how they were developed. The speakers will present the published documents in an interactive manner and discuss how individuals can use them within their own practice. The interactive educational format employed within the session will engage the audience using audience poll questions.

  • Yusheng Zhu, PhD, DABCC | Penn State University Hershey Medical Center (moderator)
  • Amy Pyle-Eilola, PhD | Nationwide Children's Hospital
  • Fang Wu, PhD, DABCC, FAACC | Saskatoon Health District
  • Lusia Sepiashvili, PhD, DABCC, FCACB | The Hospital for Sick Children
  • Octavia Peck-Palmer, PhD, FAACC | University of Pittsburgh Medical Center

THURSDAY, JULY 28

35103 Gut Check: Lab Evaluation of Celiac Disease, Inflammatory Bowel Disease, and Irritable Bowel Syndrome

Thursday, July 28, 2022 | 10:30 a.m. – 12 p.m.
Annually, millions of patients seek medical advice due to chronic gastrointestinal issues. One challenge for gastroenterologists is differentiating between highly prevalent functional disorders, such as irritable bowel syndrome (IBS), and immune-mediated conditions such as Celiac disease or inflammatory bowel disease (IBD), which require more aggressive treatment. Advancements in noninvasive serology-based diagnostic tests and fecal screening tests have reduced the need for invasive procedures. These developments simultaneously have created challenges with test-utilization due to varying diagnostic accuracies and lack of guidance. To help mitigate inappropriate testing and optimize patient outcomes, laboratory stewardship and implementation of proper clinical decision support tools are critical. During this session, current updates on analytical and clinical recommendations, developments in testing methodologies and strategies, including reflex algorithms, and gaps in the laboratory diagnosis of patients with celiac disease and IBD will be presented using illustrative cases and data.

  • Lusia Sepiashvili, PhD, DABCC, FCACB | The Hospital for Sick Children (moderator)
  • Vijayalakshmi Viji Nandakumar, PhD, DABCC | ARUP Laboratories
  • Stacy Kenyon, PhD, DABCC, NRCC | Labcorp
  • Lisa Johnson, PhD, MHS, MT (ASCP), DABCC | ARUP Laboratories

35105 Molecular Diagnostic Approaches to Navigating Healthcare Obstacles in Intersex and Transgender Patients

Thursday, July 28, 2022 | 10:30 a.m. – 12 p.m.
This session will present social challenges for the clinical management of patient populations, including transgender, intersex, and non-binary individuals, whose genders are inconsistent with laboratory reports. Such challenges present obstacles related to molecular diagnostics. Furthermore, unique issues inherent to the transgender community will be defined in complex social situations, psychological burdens, and self/gender-identifying terminology that may limit medical care. This session will explain molecular mechanisms resulting in syndromic conditions, chromosomal alterations, and other molecular changes that can lead to ambiguous genitalia and/or alternate gender assignments. Clinical presentations will be discussed in specific molecular genetic alterations. The last portion of this session will address molecular diagnostic challenges in transgender and related populations that can result in lab errors, delays in pathology reports, missed diagnosis, and potentially translate into patient harm. Molecular laboratory medicine can be strengthened through understanding and implementing practice-based changes related to these medical challenges in transgender populations.

  • Jude Abadie, PhD, DABCC, DABMG, FAACC, FACMG | Texas Tech University Health Sciences Center (moderator)
  • Julie Papango, MLS(ASCPi)CM | Albany Medical Center
  • Jeffrey SoRelle, MD | UT Southwestern Medical Center